RED BEAR News

Right of first negotiation agreements have become a staple of biopharma licensing deals—a seemingly elegant way for Big Pharma to secure optionality on promising assets while smaller biotechs gain upfront capital and partnership validation. But a new Jefferies analysis of 50 ROFN agreements over the past decade reveals an uncomfortable truth: most don't lead to acquisitions.